Keyword: Illumina

Helix is expanding its senior leadership team and acquiring app developer HumanCode, adding momentum after a planned $200 million VC round.

Merck paired up with Foundation Medicine to develop a pan-cancer diagnostic for Keytruda to measure microsatellite instability and other biomarkers.

Grail has gone 3-for-3 in venture capital rounds topping $100 million—with a $300 million addition bringing its total up to $1.5 billion since 2016.

Illumina has bought Edico Genome and its Dragen next-generation sequencing and data analysis platform. The terms of the deal were not disclosed.

The round moves 10x’s VC haul up past the $180 million mark, setting it up to introduce a range of add-ons to its core technology in the coming months.

Grail is reportedly considering squeezing in another $1 billion in funding before going public in Hong Kong this year, according to Bloomberg.

The partners will use Illumina’s NGS capabilities to create IVDs that assess tumor mutation burden and other potentially predictive biomarkers.

Illumina will use TruSight Tumor 170 as the basis for a test that identifies the NTRK fusions and RET gene alterations targeted by Loxo’s drugs.

The financing equips Oxford Nanopore to scale up its operation as it moves deeper into territory colonized by Illumina and Pacific Biosciences.

Andrew Witty will lead Optum as CEO, Novartis' operations lead André Wyss steps down, Gilead bids farewell to longtime R&D lead Norbert Bischofberger.